Loading clinical trials...
Loading clinical trials...
Single-center, Dose Escalation, Open Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma Patients With Failed TMZ Treatment
Conditions
Interventions
TG02 capsules oral administration, BIW in every 28d
TG02 capsules oral administration, BIW in every 28d
+1 more
Locations
1
China
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
Start Date
March 22, 2019
Primary Completion Date
August 1, 2020
Completion Date
October 31, 2020
Last Updated
April 14, 2020
NCT06660056
NCT00890786
Lead Sponsor
Lee's Pharmaceutical Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions